论文部分内容阅读
目的观察多西他赛联合替吉奥新辅助化疗治疗进展期胃癌的疗效。方法选取医院收治的进展期胃癌患者132例为研究对象,随机分为观察组和对照组,每组66例。观察组采用多西他赛联合替吉奥新辅助化疗治疗,对照组采用铂类加氟尿嘧啶治疗。观察2组患者化疗后疗效及化疗后不良反应。结果观察组总有效率为98.49%,高于对照组的80.30%(P<0.01);观察组不良反应发生率均低于对照组(P<0.01)。结论多西他赛联合替吉奥新辅助化疗应用于进展期胃癌的治疗,临床治疗效果更好,且患者化疗后不良反应发生率更低,能够有效降低患者患者痛苦的程度,具有临床推广价值。
Objective To observe the efficacy of docetaxel in combination with neoadjuvant chemotherapy for advanced gastric cancer. Methods A total of 132 patients with advanced gastric cancer admitted to our hospital were selected as study subjects and randomly divided into observation group and control group with 66 cases in each group. In the observation group, docetaxel was used in combination with neoadjuvant chemotherapy for the treatment of patients, while the control group was treated with platinum plus fluorouracil. Two groups of patients after chemotherapy efficacy and adverse reactions after chemotherapy. Results The total effective rate in the observation group was 98.49%, which was higher than that in the control group (80.30%, P <0.01). The incidence of adverse reactions in the observation group was lower than that in the control group (P <0.01). Conclusion Docetaxel combined with neoadjuvant chemotherapy for the treatment of advanced gastric cancer, clinical effect is better, and patients with lower incidence of adverse reactions after chemotherapy, patients with pain can effectively reduce the degree of clinical promotion value .